ArticleJBMR plus2026
Generation and characterization of a novel inducible Sost_P2A_CreERT2 mouse model with high specificity for osteocytes.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We have developed a novel Sost_P2A_CreERT2 model, in which the CreERT2 fusion sequence was knocked into the 5'UTR of the endogenous Sost gene (both exons left undisturbed) and is preceded by an upstream P2A linker sequence to promote separate translation of the CreERT2 message. These mice were crossed with the Ai9 (TdTomato, TdT) mouse, and the Sost_P2A_CreERT2/Ai9 male and female offspring were aged for either 2 or 5 mo. Cre activity was then induced by 5 daily injections of 75 mg/kg tamoxifen and TdT expression was examined in skeletal and soft tissues 7 days after the final tamoxifen injection. Quantitation of reporter positive osteocytes showed lowest percent expression in femoral trabecular bone ranging from 24% to 49% with 0.3%-4.7% positive cells or "leakiness" in vehicle injected mice. Femoral cortical bone, L2 vertebra, and calvaria showed higher induction ranging from 60% to 90% depending on the age and sex of the mice, with 1%-18% leakiness. TdT expression was not observed in any cells on the periosteal or endosteal bone surfaces or in the bone marrow. No TdT expression was observed at either age or sex in muscle, brain, lung, kidney, or other soft tissues including heart. However, TdT positive cells were observed in the ascending aorta, appearing to be vascular smooth muscle cells. Lowering the dose of tamoxifen to a single injection of 10 mg/kg induced minimal expression in the aorta while inducing significant expression in only in osteocytes. In summary, this novel Sost_P2A_CreERT2 model shows high specificity for osteocytes and can be fine-tuned with varying doses of tamoxifen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.